JP2024522184A - Ｓｅｔｄ２阻害剤との併用療法 - Google Patents

Ｓｅｔｄ２阻害剤との併用療法 Download PDF

Info

Publication number
JP2024522184A
JP2024522184A JP2023575830A JP2023575830A JP2024522184A JP 2024522184 A JP2024522184 A JP 2024522184A JP 2023575830 A JP2023575830 A JP 2023575830A JP 2023575830 A JP2023575830 A JP 2023575830A JP 2024522184 A JP2024522184 A JP 2024522184A
Authority
JP
Japan
Prior art keywords
alkyl
group
cycloalkyl
hydroxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522184A5 (enExample
Inventor
マリア アレジャンドラ ライモンディ，
ジェニファー アン トットマン，
ビニー モットワニ，
キャサリン ルイーズ コスモポロス，
ドロシー ブラッチ，
ダニエル ティー． ドランスフィールド，
Original Assignee
エピザイム，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピザイム，インコーポレイティド filed Critical エピザイム，インコーポレイティド
Publication of JP2024522184A publication Critical patent/JP2024522184A/ja
Publication of JP2024522184A5 publication Critical patent/JP2024522184A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023575830A 2021-06-09 2022-06-08 Ｓｅｔｄ２阻害剤との併用療法 Pending JP2024522184A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208882P 2021-06-09 2021-06-09
US63/208,882 2021-06-09
PCT/US2022/032718 WO2022261243A1 (en) 2021-06-09 2022-06-08 Combination therapies with setd2 inhibitors

Publications (2)

Publication Number Publication Date
JP2024522184A true JP2024522184A (ja) 2024-06-11
JP2024522184A5 JP2024522184A5 (enExample) 2025-06-16

Family

ID=84425539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575830A Pending JP2024522184A (ja) 2021-06-09 2022-06-08 Ｓｅｔｄ２阻害剤との併用療法

Country Status (10)

Country Link
US (1) US20240299352A1 (enExample)
EP (1) EP4351552A4 (enExample)
JP (1) JP2024522184A (enExample)
KR (1) KR20240019241A (enExample)
CN (1) CN117794543A (enExample)
AU (1) AU2022288073A1 (enExample)
CA (1) CA3221071A1 (enExample)
IL (1) IL308868A (enExample)
MX (1) MX2023014663A (enExample)
WO (1) WO2022261243A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272379B2 (en) 2017-08-14 2025-11-01 Epizyme Inc Methods of treating cancer by inhibiting setd2
JP7627209B2 (ja) 2018-08-14 2025-02-05 エピザイム，インコーポレイティド 置換インドール及びその使用方法
CN121695288A (zh) 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法
WO2025034951A1 (en) * 2023-08-09 2025-02-13 Enanta Pharmaceuticals, Inc. Pharmaceutical compounds and compositions as c-kit kinase inhibitors
TW202532067A (zh) * 2023-12-13 2025-08-16 大陸商正大天晴藥業集團股份有限公司 含有吡唑環及雙環雜芳基的化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017509682A (ja) * 2014-04-04 2017-04-06 イオメット ファーマ リミテッド 医療で使用されるインドール誘導体
WO2020037079A1 (en) * 2018-08-14 2020-02-20 Epizyme, Inc. Substituted indoles and methods of use thereof
JP2020530844A (ja) * 2017-08-14 2020-10-29 エピザイム，インコーポレイティド Ｓｅｔｄ２を阻害することにより癌を処置する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9446064B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
US20170232030A1 (en) * 2014-08-13 2017-08-17 Epizyme, Inc. Combination therapy for treating cancer
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2020112872A1 (en) * 2018-11-30 2020-06-04 Epizyme, Inc. Methods of treating whsc1-overexpressing cancers by inhibiting setd2
CN121695288A (zh) * 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017509682A (ja) * 2014-04-04 2017-04-06 イオメット ファーマ リミテッド 医療で使用されるインドール誘導体
JP2020530844A (ja) * 2017-08-14 2020-10-29 エピザイム，インコーポレイティド Ｓｅｔｄ２を阻害することにより癌を処置する方法
WO2020037079A1 (en) * 2018-08-14 2020-02-20 Epizyme, Inc. Substituted indoles and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI, CHEN ET AL.: ""Finding an easy way to harmonize: a review of advances in clinical research and combination strate", CLINICAL EPIGENETICS, vol. 13, no. 1, JPN6026032058, 24 March 2021 (2021-03-24), pages 62, ISSN: 0005919580 *

Also Published As

Publication number Publication date
EP4351552A4 (en) 2025-06-18
KR20240019241A (ko) 2024-02-14
US20240299352A1 (en) 2024-09-12
CN117794543A (zh) 2024-03-29
MX2023014663A (es) 2024-05-08
CA3221071A1 (en) 2022-12-15
AU2022288073A1 (en) 2023-12-07
WO2022261243A1 (en) 2022-12-15
IL308868A (en) 2024-01-01
EP4351552A1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
JP7627209B2 (ja) 置換インドール及びその使用方法
CA3087089C (en) Fused ring compounds
TWI828677B (zh) 甲基修飾酵素之調節劑、其組成物及用途
CN115380033B (zh) Setd2抑制剂和相关方法和用途，包括组合疗法
CA2926328C (en) Substituted quinazolinyl and quinolinyl derivatives and pharmaceutical compositions thereof useful as inhibitors of kras g12c
CA3215949A1 (en) Oxazepine compounds and uses thereof in the treatment of cancer
JP2022507527A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
CA3144859A1 (en) Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
EP4351552A1 (en) Combination therapies with setd2 inhibitors
CN114502536A (zh) 作为激酶抑制剂的杂环化合物
CA2692611A1 (en) Di(arylamino)aryl compounds
EP3271333B1 (en) Usp7 inhibitor compounds and methods of use
WO2021074251A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives and their use in the treatment of cancer
JP2016536308A (ja) タンキラーゼ阻害剤としてのピリド［２，３−ｄ］ピリミジン−４−オン化合物
TW201902892A (zh) 化合物
EP3331873B1 (en) A 4-(3-pyrazolylamino)-benzimidazole derivative as jak1 inhibitor for treating cancer
HK40084091A (en) Setd2 inhibitors and related methods and uses, including combination therapies
CN116102545B (zh) 一种二芳基脲类PI3K/mTOR/HDAC多靶点抑制剂及其药物组合物和应用
RU2836176C2 (ru) Имидазопиримидины как ингибиторы eed и их применение
CN118401527A (zh) 化合物
CA2981530A1 (en) Substituted quinazoline compounds and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260729